Lifestyle
- Stress management techniques
- Regular moderate exercise
- Adequate sleep
Immunoglobulin A · IgA · Salivary IgA
The test quantifies the concentration of Immunoglobulin A in the blood or saliva, reflecting mucosal immune function.
Reference ranges may vary slightly based on laboratory standards.
Immunoglobulin A (IgA) is a critical component of the immune system, primarily found in mucosal areas such as the gut, respiratory tract, and urogenital tract, as well as in saliva, tears, and breast milk. It plays a vital role in mucosal immunity by preventing the colonization of pathogens and maintaining the balance of the gut microbiota. Clinically, IgA levels can reflect various conditions. Elevated IgA levels are often associated with autoimmune diseases such as IgA nephropathy, which is characterized by IgA deposits in the kidneys leading to chronic kidney disease. Conversely, low IgA levels may indicate immunodeficiency disorders. In the context of athletic performance and biohacking, IgA is of interest due to its role in stress response and mucosal immunity, which can be crucial for recovery and overall health. Researchers have found that interventions like L-Theanine can modulate salivary IgA levels, suggesting potential for stress management. However, IgA levels can be influenced by several factors, including stress, infections, and certain medications. Time of day and fasting status do not significantly affect IgA levels, but acute stress can cause transient changes. Therefore, interpreting IgA levels requires consideration of these confounding factors.
Klinische Bedeutung
Elevated IgA levels may indicate autoimmune conditions like IgA nephropathy, while reduced levels can suggest immunodeficiency disorders. Monitoring IgA can aid in assessing immune function and disease progression.
Progressively rising IgA levels may suggest worsening of autoimmune conditions or chronic infections. Re-test in 4-6 weeks if levels are outside the normal range.
Progressively falling IgA levels could indicate improvement in autoimmune conditions or response to treatment.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen.
IgA levels may vary throughout the day; consistent timing is recommended for repeat tests.
Testing Frequency
Annually for general health monitoring, more frequently if indicated by health conditions.
May affect
Current research suggests that while IgA levels and their complexes are associated with disease progression in conditions like IgA nephropathy, reference ranges and optimal targets for these biomarkers remain poorly defined. Researchers have not yet established the specific confounders influencing IgA responses in diverse populations or the long-term implications of emerging therapies targeting IgA pathways. Additionally, clinical questions about the predictive value of IgA-related biomarkers for treatment response and disease outcomes remain unanswered.
1,145
Total Citations
11
Human/RCT
8.7
Avg. Influence
2025
Latest
This study examined the effects of L-Theanine on stress responses, specifically measuring salivary immunoglobulin A (s-IgA). Researchers observed that L-Theanine intake reduced heart rate and s-IgA responses during stress tasks compared to placebo. The findings suggest that L-Theanine may help mitigate stress-related physiological responses.
This study examined Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, which can lead to chronic kidney disease. Researchers found significant variability in patient outcomes and highlighted the need for better biomarkers to avoid invasive kidney biopsies. Current treatments are limited, but new therapeutic approaches are being explored in clinical trials.
Researchers identified that gut microbiota-specific IgA+ B cells can traffic to the central nervous system (CNS) in multiple sclerosis (MS). The study found a strong IgA enrichment in active MS, suggesting a role for IgA in neuroinflammation. This highlights the potential of IgA as a biomarker for MS.
This study examined immunoglobulin A (IgA) deficiency, the most common primary immunoglobulin deficiency, and its association with infections and autoimmune diseases. Researchers noted that while many individuals are asymptomatic, those with symptoms often experience severe infections.
Researchers studied the effects of Telitacicept on biomarkers in patients with Immunoglobulin A nephropathy (IgAN). They found significant reductions in galactose-deficient-IgA1 and IgA-containing immune complexes after treatment, which correlated with decreased proteinuria. The study indicates potential biomarkers for monitoring treatment response in IgAN.
Researchers identified immunoglobulin A (IgA) antibodies against myelin oligodendrocyte glycoprotein (MOG) in a subgroup of patients with central nervous system demyelination. This finding suggests that MOG-IgA may serve as a novel diagnostic biomarker for certain demyelinating diseases.
Researchers explored the role of microscopic hematuria as a potential risk factor for progression in immunoglobulin A nephropathy (IgAN). The study discussed the challenges in standardizing hematuria assessments and called for its inclusion in clinical decision-making to guide treatment strategies in IgAN.
This study reported two cases of IgA vasculitis following COVID-19 vaccination, highlighting the potential for vaccines to trigger this condition. Researchers noted that both patients responded well to treatment with prednisolone, resolving their symptoms quickly.
Researchers highlighted the role of immunoglobulin A (IgA) in the immune response to SARS-CoV-2 infection, noting its significance as a diagnostic and prognostic marker. The study emphasized the potential of IgA detection tests for early diagnosis and treatment of COVID-19.
Researchers found that Immunoglobulin A nephropathy (IgAN) is characterized by complex immune mechanisms and proposed a new 'spiral hypothesis' to explain its chronic nature. The study highlights the potential of targeted therapies that address both immune drivers and fibrotic pathways. It emphasizes the importance of personalized treatment strategies based on biomarkers.
Research publications about Immunglobulin A over time
5totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer